為了解世界衛(wèi)生組織（WHO）有關(guān)藥物警戒系統(tǒng)的評估指標(biāo)的開發(fā)和應(yīng)用情況，給我國藥物警戒系統(tǒng)的建設(shè)情況和活動進(jìn)展的評估提供參考，對2015年WHO出版的《世界衛(wèi)生組織藥物警戒指標(biāo)體系：評估藥物警戒系統(tǒng)的實踐手冊》（v1.0）的內(nèi)容進(jìn)行全面詳細(xì)的介紹，并對該手冊的實際應(yīng)用做進(jìn)一步分享。WHO致力于推動國際藥物警戒的發(fā)展，不僅制定了專門的實踐手冊以促進(jìn)全球?qū)λ幬锞渲笜?biāo)的理解，還通過多方合作共同推動藥物警戒指標(biāo)的發(fā)展和應(yīng)用，藥物警戒指標(biāo)的設(shè)置比較靈活，可根據(jù)使用環(huán)境的實際情況進(jìn)行適當(dāng)調(diào)整。

In order to understand the development and application of World Health Organization (WHO) pharmacovigilance indcators, and to provide a reference for the evaluation of the construction and activity progress of China pharmacovigilance system, this article was based on the "WHO Pharmacovigilance Indicators: a Practical Manual for the Assessment of Pharmacovigilance Systems" (v1.0) published by WHO in 2015. This paper provided a comprehensive and detailed introduction, and shared the practical application of the manual. It can be concluded that WHO was committed to promoting the development of international pharmacovigilance. It had't only formulated a special practice manual to promote global understanding of pharmacovigilance indcators, but also promoted the development and application of pharmacovigilance indcators through multi-party cooperation. The setting was more flexible and can be adjusted appropriately according to the actual conditions of the use environment.

2019年廣東省藥品不良反應(yīng)監(jiān)測中心委托項目